1. Pentoxifylline inhibits TLR- and inflammasome-mediated in vitro inflammatory cytokine production in human blood with greater efficacy and potency in newborns
- Author
-
Lukasz S. Ozog, Esther M. Speer, David J. Dowling, Jie Yang, Ofer Levy, Geetika Kennady, and Jianjin Xu
- Subjects
Adult ,Lipopolysaccharides ,0301 basic medicine ,Time Factors ,Inflammasomes ,medicine.medical_treatment ,Interleukin-1beta ,Anti-Inflammatory Agents ,Inflammation ,Pharmacology ,Pentoxifylline ,Proinflammatory cytokine ,03 medical and health sciences ,Adenosine Triphosphate ,0302 clinical medicine ,medicine ,Humans ,RNA, Messenger ,Dose-Response Relationship, Drug ,Interleukin-6 ,Tumor Necrosis Factor-alpha ,business.industry ,Toll-Like Receptors ,Age Factors ,Imidazoles ,Infant, Newborn ,Interleukin ,Inflammasome ,Fetal Blood ,Interleukin-10 ,030104 developmental biology ,Cytokine ,Pediatrics, Perinatology and Child Health ,TLR4 ,Tumor necrosis factor alpha ,Inflammation Mediators ,medicine.symptom ,business ,Biomarkers ,030217 neurology & neurosurgery ,medicine.drug - Abstract
Toll-like receptor (TLR)-mediated inflammation may contribute to neonatal sepsis, for which pentoxifylline (PTX), a phosphodiesterase inhibitor that raises intracellular cAMP, is a candidate adjunctive therapy. We characterized the anti-inflammatory effects of PTX toward TLR-mediated production of inflammatory (tumor necrosis factor (TNF) and interleukin (IL)-1β) and proresolution (IL-6 and IL-10) cytokines in human newborn and adult blood. Newborn cord and adult blood were treated with PTX (50–400 µmol/l) before, during or after stimulation with LPS (TLR4 agonist), R848 (TLR7/8 agonist) or LPS/ATP (inflammasome activation). Cytokines were measured by multiplex assay (supernatants), intracellular cytokines and signaling molecules by flow cytometry, and mRNA by quantitative real-time PCR. Whether added 2 h pre-, simultaneously to, or 2 h post-TLR stimulation, PTX inhibited TLR-mediated cytokine production in a concentration-dependent manner, with greater efficacy and potency in newborn blood, decreasing intracellular TNF and IL-1β with relative preservation of IL-10 and IL-6. PTX decreased TLR-mediated TNF mRNA while increasing IL-10 mRNA. Neonatal plasma factors contributed to the anti-inflammatory effects of PTX in newborn blood that were independent of soluble TNF receptor concentrations, p38 MAPK phosphorylation and IĸB degradation. PTX is a potent and efficacious inhibitor of TLR-mediated inflammatory cytokines in newborn cord blood and a promising neonatal anti-inflammatory agent.
- Published
- 2017
- Full Text
- View/download PDF